nafamostat and favipiravir

nafamostat has been researched along with favipiravir in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	8 (100.00)	2.80

Authors

Authors	Studies
Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X	1
Doi, K; Hayase, N; Ikeda, M; Morimura, N; Moriya, K	1
Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N	1
Inoue, KI; Sagawa, T; Takano, H	1
Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T	1
Fätkenheuer, G; Malin, JJ; Rybniker, J; Simonis, A; Theobald, SJ	1
Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A	1
Adachi-Katayama, M; Araoka, H; Harada, S; Hashimoto, H; Hataji, O; Igari, H; Ikeda, M; Inoue, JI; Jubishi, D; Kanematsu, A; Kanno, Y; Kashiwabara, K; Kawasuji, H; Mitsumura, T; Miyazaki, Y; Moritoyo, T; Moriya, K; Nakamura, Y; Nakano, Y; Ogura, S; Okamoto, K; Okugawa, S; Otani, A; Oyabu, T; Saito, M; Sakao, S; Seto, Y; Shinohara, T; Takeshita, Y; Tsushima, K; Tsutsumi, T; Uchida, Y; Wakimoto, Y; Yamamoto, Y; Yamasaki, K; Yamashita, M; Yatera, K	1

Reviews

3 review(s) available for nafamostat and favipiravir

Article	Year
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Journal of medicinal chemistry, 2020, 11-25, Volume: 63, Issue:22 Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries	2020
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. Clinical rheumatology, 2020, Volume: 39, Issue:11 Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed	2020
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO molecular medicine, 2021, 01-11, Volume: 13, Issue:1 Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Benzamidines; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guanidines; Guanine; Humans; Indoles; Lopinavir; Protease Inhibitors; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Virus Internalization; Virus Replication	2021

Trials

1 trial(s) available for nafamostat and favipiravir

Article	Year
Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023, Volume: 128 Topics: Antiviral Agents; COVID-19; Disease Progression; Humans; SARS-CoV-2; Single-Blind Method; Treatment Outcome	2023

Article

Year

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023, Volume: 128

Topics: Antiviral Agents; COVID-19; Disease Progression; Humans; SARS-CoV-2; Single-Blind Method; Treatment Outcome

2023

Other Studies

4 other study(ies) available for nafamostat and favipiravir

Article	Year
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Critical care (London, England), 2020, 07-03, Volume: 24, Issue:1 Topics: Aged; Amides; Benzamidines; Coronavirus Infections; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Female; Guanidines; Humans; Male; Middle Aged; Pyrazines; Treatment Outcome	2020
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients. Critical care (London, England), 2020, 08-12, Volume: 24, Issue:1 Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2	2020
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors. Critical care (London, England), 2020, 08-18, Volume: 24, Issue:1 Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2	2020
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. Endocrine journal, 2021, Apr-28, Volume: 68, Issue:4 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination	2021